布格替尼治疗晚期NSCLC的早期肺部不良事件
该研究汇总了布格替尼在1至3期研究中的早期肺部不良事件(EOPEs),发现其发生率随起始剂量增加,在90 mg起始剂量下至少可能相关的EOPEs发生率为4.5%,中位发生时间2天。3%的患者因3级及以上事件停药,1.5%的患者经处理后可继续用药。多因素分析显示EOPEs与ECOG体能状态和既往治疗方案数相关。
要点
- 布格替尼相关EOPEs多发生于用药后7天内,中位起病时间2天。
- 90 mg起始剂量下至少可能相关EOPEs发生率为4.5%(20/440)。
- 3%患者因3级及以上EOPEs停药,1.5%经处理可继续用药。
核心结论
- 部分NSCLC患者在接受布格替尼治疗后数天内可出现临床明显的早期肺部不良事件。
- 识别与EOPEs风险升高相关的临床参数可能有助于减轻此类事件。
研究设计与样本
- 基于1/2期研究、2期ALK in Lung Cancer Trial of AP26113研究和3期ALK in Lung Cancer Trial of Brigatinib in first Line研究的汇总分析。
- 1/2期研究纳入晚期恶性肿瘤患者,布格替尼剂量范围30 mg至300 mg每日一次。
- 2期研究纳入克唑替尼治疗后晚期ALK+ NSCLC患者,接受90 mg每日一次或90 mg每日一次7天后180 mg每日一次。
- 3期研究纳入初治ALK+ NSCLC患者,接受布格替尼180 mg每日一次(7天90 mg导入)或克唑替尼250 mg每日两次。
主要发现
- 1/2期、2期和3期研究中,至少可能与布格替尼相关的EOPEs发生率分别为8%(11/137)、6%(14/219)和3%(4/136)。
- EOPEs发生频率似乎随起始剂量增加而升高。
- 在90 mg每日一次起始剂量(单药或剂量递增方案)下,至少可能相关事件发生率为4.5%(20/440),中位起病时间2天。
- 12例患者(3%)发生3级及以上事件并导致布格替尼停药。
- 7例患者(1.5%)发生1至2级事件,经布格替尼中断、类固醇或补氧等处理后成功继续布格替尼治疗。
关键数值与推荐
- 在未调整logistic回归分析中,EOPEs发生与患者年龄每连续增加10岁显著相关。
- 在多因素回归分析中,EOPEs发生与ECOG体能状态和既往治疗方案数相关。
临床怎么用
- 使用布格替尼治疗NSCLC时,应关注用药后7天内尤其是前2天内的早期肺部症状。
- 对具有ECOG体能状态较差或既往治疗方案数较多等高危因素的患者,可考虑加强监测。
- 发生1至2级EOPEs时,经中断用药、类固醇或补氧等处理后可尝试继续布格替尼治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We evaluated pulmonary adverse events observed within 7 days after drug initiation in phase 1 to phase 3 studies of the anaplastic lymphoma kinase (ALK) inhibitor brigatinib. METHODS: The phase 1/2 study enrolled patients with advanced malignancies (dosage range, 30 mg-300 mg once a day); the phase 2 ALK in Lung Cancer Trial of AP26113 study treated patients with advanced ALK+ NSCLC postcrizotinib at either 90 mg once a day or 90 mg once a day for 7 days followed by 180 mg once a day; and the phase 3 ALK in Lung Cancer Trial of Brigatinib in first Line study treated inhibitor-naive patients with ALK+ NSCLC with brigatinib (180 mg once a day [with 7-day lead-in at 90 mg once a day]) or crizotinib (250 mg twice a day). Early-onset pulmonary events (EOPEs) at least possibly associated with brigatinib were captured. RESULTS: In the phase 1/2, ALK in Lung Cancer Trial of AP26113, and ALK in Lung Cancer Trial of Brigatinib in first Line studies, 8% (11/137), 6% (14/219), and 3% (4/136) of patients, respectively, had at least possible EOPEs on brigatinib, with frequency appearing to increase with the starting dosage. Across trials, at the 90-mg once-a-day starting dosage (alone or step-up dosing), 4.5% of patients (20/440) had at least possible events (median time to onset, 2 days). A total of 12 patients (3%) had grade 3 or higher events leading to brigatinib discontinuation. Seven patients (1.5%) had grade 1 to grade 2 events and successfully continued brigatinib with or without brigatinib interruption, steroids, or supplemental oxygen. In pooled analysis of these trials, occurrence of EOPEs was significantly associated with continuous 10-year increases in patient age in unadjusted logistic regression analysis, and with Eastern Cooperative Oncology Group performance status and number of previous regimens in multivariate regression. CONCLUSIONS: Clinically apparent EOPEs can occur within days of commencing brigatinib in a subset of patients with NSCLC. Identifying clinical parameters associated with a higher risk of developing such events may help mitigate these events.
引用
- Ng TL, Narasimhan N, Gupta N, et al. Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC. J Thorac Oncol. 2020. PMID: 32135189. doi:10.1016/j.jtho.2020.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。